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Background: Trends and predictors of domestic spending from public sources provide national authorities and
international donors with a better understanding of the HIV financing architecture, the fulfillment of governments’
commitments and potential for long-term sustainability.
Methods: We analyzed government financing of HIV using evidence from country reports on domestic spending. Panel
data from 2000 to 2010 included information from 647 country-years amongst 125 countries. A random-effects model
was used to analyze ten year trends and identify independent predictors of public HIV spending.
Results: Low- and middle-income countries spent US$ 2.1 billion from government sources in 2000, growing to US$ 6.6
billion in 2010, a three-fold increase. Per capita spending in 2010 ranged from 5 cents in low-level HIV epidemics in the
Middle East to US$ 32 in upper-middle income countries with generalized HIV epidemics in Southern Africa. The average
domestic public spending per capita was US$ 2.55. The analysis found that GDP per capita and HIV prevalence are
positively associated with increasing levels of HIV-spending from public sources; a 10 percent increase in HIV prevalence is
associated with a 2.5 percent increase in domestic funding for HIV. Additionally, a 10 percent increase in GDP per capita is
associated with an 11.49 percent increase in public spending for HIV and these associations were highly significant.
Conclusion: Domestic resources in low- and middle-income countries showed a threefold increase between 2000 and
2010 and currently support 50 percent of the global response with 41 percent coming from sub-Saharan Africa. Domestic
spending in LMICs was associated with increased economic growth and an increased burden of HIV. Sustained increases
in funding for HIV from public sources were observed in all regions and emphasize the increasing importance of
government financing.Background
Over the past 10 years, the world has seen a dramatic
scale up of funding in order to combat HIV worldwide.
In addition to their domestic response, countries have ex-
perienced various levels of bilateral support, primarily
from the U.S. President's Emergency Plan for AIDS Relief
(PEPFAR), the Organization for Economic Co-operation
and Development (OECD) countries and also from
multilateral mechanisms such as The Global Fund to
Fight AIDS, Tuberculosis and Malaria (GF), the United
Nations system and UNITAID. Some countries, specific-
ally in sub-Saharan Africa (SSA) are highly dependent on* Correspondence: Carlos_avila@abtassoc.com
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reproduction in any medium, provided the ordonor funding which raises concerns about the sustain-
ability of their domestic HIV response [1]. The economic
crisis has created widespread concerns that funding
shortages will have an adverse impact on public spending
affecting the national resources devoted to HIV.
Global spending on HIV is increasing; it is up 11% in
2011 over 2010 at US$ 16.8 billion. International assistance
is essentially flat and some donor countries are reducing
their funding [2]. Because of the scarcity of health funding,
it is important to implement robust financial tracking
mechanisms to monitor political commitments and under-
stand the funding trends in the health sector. This will
allow policy makers and countries to evaluate their spend-
ing patterns and strategically scale up effective interven-
tions with high impact as well as planning for future
demand without interruptions to supplies of antiretrovirald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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understand the independent predictors of domestic spend-
ing on HIV between 2000 and 2010 and to examine re-
gional HIV spending trends.
Methods
Data sources
In order to evaluate HIV spending, a dataset was cons-
tructed by combining country reports that included the
total amount of domestic spending at the country level.
The domestic/public HIV spending dataset was cons-
tructed from the national data reported for United
Nations General Assembly Special Session (UNGASS)
report indicator number 1 based on the National AIDS
Spending Assessment (NASA). The AIDS resource track-
ing methodology and definitions are explained elsewhere
[3,4]. Domestic-public spending on HIV is the amount of
funding from a country’s national resources that has been
allocated and spent on HIV specific activities, human re-
sources and infrastructure. HIV public-domestic expen-
ditures encompasses all funds that are spent inside of the
country from government sources [4]. We excluded do-
mestic private and international sources of funding.
Research questions
We identified independent predictors of domestic/public
spending; we focused the analysis on several plausible
variables using existing literature, that may influence a
government’s decision to invest in HIV, including the na-
tional economy expressed as Gross Domestic Product
(GDP) per capita, HIV prevalence and governance indi-
cators [1]. It is hypothesized that as HIV prevalence in-
creases in a country, the domestic/public spending will
also increase. This response is explained by the increased
priority being given to HIV as it becomes a more signifi-
cant issue in the country’s population. Due to the vast
difference in prevalence across regions, regional vari-
ables were employed to account for this variation. Add-
itionally, a country’s level of GDP per capita is also
hypothesized to lead to increased investment in domestic/
public spending on HIV. It is assumed that spending on
HIV is a normal good; this means that as income in-
creases so will the domestic investment in the country’s
HIV spending. Governance is another important area to
measure as well as the burden of other diseases in the
country. It is hypothesized that countries with more
stable and less corrupt governments will invest more
funding in HIV. For the purposes of this paper we mea-
sured these concepts using the World Bank’s governance
indicators [5].
Analytical strategy
The panel consisted of 678 country years of observations
covering a span of 10 years and 129 countries. 512 ofthese data points were reported and validated from country
reports. The average number of observations per country
was 4.6 and the average domestic public spending per
capita was US$ 2.55. The number of independent country
observations ranged from 17 in 2000 to 101 in 2008. The
final regression model included 647 country years and 125
countries due to the exclusion of outliers. The regression
diagnostic tests (leverage, Cook's distance, dfbeta) indi-
cated that Namibia, South Africa, Botswana and
Swaziland were outliers and they were excluded from
the model.
The independent variables that were used in the ana-
lysis at the country level were: GDP per capita, HIV
prevalence, an array of governance indicators and re-
gional variables. HIV prevalence is the percentage of
people living with HIV. The governance variables in-
cluded measures of accountability, corruption, govern-
ment efficiency, political stability, regulatory quality and
rule of law. Because these variables were highly corre-
lated we used only political stability to represent the
overall concept of governance. GDP per capita and HIV
prevalence were log transformed to normalize the resid-
uals and correct skewness and kurtosis. The dependent
variable was the domestic public spending per capita on
HIV; this variable was also log transformed.
Panel data is likely to violate the Gauss Markov as-
sumptions of independence; therefore, several models
were tested—both random and fixed effects models with
clustered standard errors. The Hausman and Sargan-
Hansen tests confirmed the random effects model was
the best specification. The projections are not intended
to forecast domestic/public spending on HIV far into
the future, due to the instability of public and donor
funding, but to show current and past trends.
Results
Low- and middle-income countries spent a cumulative
total of US$ 43.5 billion from domestic public sources
between 2000 and 2010. Out of this total; 35 percent
was spent in sub-Saharan Africa (US$ 12.9 billion), 32.8
percent in Latin America (US$ 12.1 billion), 12 percent
in South-East Asia (US$ 4.42 billion) and 9.5 percent in
Eastern Europe and Central Asia (US$ 3.52 billion). Total
domestic spending in low-and middle-income countries
showed a relative increase of 314 percent during the ten-
year period.
Descriptive statistics and panel sample size
Table 1 shows an overview of the domestic/public spend-
ing, HIV prevalence and GDP per capita. The mean of
selected independent variables and the dependent vari-
able are shown by region, due to the large amount of
variation that occurs across 145 countries with very dif-
ferent spending priorities and epidemiological profiles.
Table 1 Descriptive statistics
Variable SSA LAC Other
countries
Mean Mean Mean Sample Size
(SE) (SE) (SE) (SSA, LAC, Other)
Domestic/Public Spending
per capita US$
5.52 1.88 1.07 208, 154,
(17.33) (1.61) (3.16) 314
HIV Prevalence 6.97 0.585 0.496 418, 187,
(7.12) (.332) (.617) 616
GDP per capita US$ 2,023 4,538 3,884 435, 187,
(2917) (2859) (3561) 787
*Standard errors indicated by ().
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domestic/public spending as well as a much higher preva-
lence rate than the other regions. These variations between
regions are important differences that are accounted for in
the model.
Model specification and independent predictors
of domestic public spending
The key estimation results from the model including
prevalence, GDP per capita, a variety of governance indica-
tors and regional controls are reported below in Table 2.
The final prediction model (Table 2, model 4) was a ran-
dom effects model taking the natural logarithm of HIV
prevalence, the natural logarithm of GDP per capita
and including regional controls for sub-Saharan Africa
(SSA) and Latin America (LAC). The coefficients from the
fixed and random effects model were similar in magnitude.
Due to the log-log specification in the model the results
can be interpreted as elasticities. Therefore, a 10 percent
increase in HIV prevalence is associated with a 2.5 percent
increase in domestic/public funding for HIV. Additionally,
a 10 percent increase in GDP per capita is associated with
an 11.49 percent increase in domestic/public spending for
HIV. All of the variables in the prediction model (Table 2,
model 4) were highly significant at the .001 percent level.
We found that political stability was not significantly as-
sociated with domestic/public spending on HIV.
As an alternative estimation method, we looked at HIV
domestic/public spending per person living with HIV. All
of the coefficients retained the same sign and significance
level except that prevalence became negative.
Trends in domestic-public spending
Globally, domestic/public funding of HIV in low- and
middle-income countries has increased from US$ 2.15
billion in 2000 to more than US$ 6.6 billion in 2010.
This growth rate has mostly been constant, but there
was an overall stagnation between 2008 and 2009 as theglobal economy was shaken. Regionally, SSA overtook
LAC in 2004 and has remained the region with the highest
amount of government financed resources devoted to HIV.
Figure 1 shows the total domestic public spending for HIV
by region between 2000 and 2010. The growth in SSA was
mainly driven by upper-middle income countries. Of these
six countries, Botswana and South Africa are the primary
drivers of the growth in HIV spending in SSA. If these
upper-middle income countries are excluded, the growth
of domestic/public funding in SSA almost mirrors the
growth of South and South-East Asia (SSEA).
Overall, per capita HIV spending from domestic sources
increased from US$ 0.31 in 2000 to US$ 1.11 in 2010
and varied widely by type of epidemic, income level and
region (Table 3). In 2010 spending ranged from 5 cents
in low-level epidemics in the Middle East and North
Africa to US$ 32 in upper-middle income countries
with generalized epidemics in East and Southern Africa.
Countries with low-level epidemics spent US$ 0.34 and
those with generalized epidemics US$ 3.04 per capita.
Low-income countries spent an average of US$ 0.45
per capita and upper-middle-income countries almost
US$ 5.00. Regional spending also showed wide vari-
ation with per-capita spending from US$ 0.20 in the
Middle East and North Africa to US$ 3.45 in sub-Saharan
Africa. Additional file 1: Appendix 1 and Additional file 1:
Appendix 2 present regional and country domestic public
expenditures on HIV based on our full database of 1595
country years from 145 low- and middle-income countries.
All the predicted values were substituted by reported coun-
try data when available.
Figure 2 shows the relationship between GDP, on the
horizontal axis, the level of domestic per-capita spending
on HIV, on the vertical axis, and HIV prevalence,
depicted using a spread of bubbles of different sizes. The
two regression lines demonstrate the different in trajec-
tory between high and low HIV prevalence countries
along with their GDP and domestic health spending.
Poor countries with low domestic spending on HIV and
high prevalence are located in the lower left quadrant
and have large bubbles. These countries are especially
vulnerable and more likely unable to invest enough re-
sources to control the spread of HIV due to their low in-
come levels and high rates of HIV prevalence. This is the
case for Zimbabwe, Kenya, Uganda and Malawi, which
have low domestic spending on HIV, a high HIV burden
and low economic capacity.
Figure 3 presents the trends of domestic public spend-
ing in all developing countries. There was a substantial
increase in government financing for HIV with substan-
tial increases in sub-Saharan Africa, Eastern Europe and
Asia. Even in low-income sub-Saharan Africa, aggre-
gated public financing increased from US$ 639 million
to US$ 2.5 billion in 2010, an almost four-fold increase.
Table 2 Domestic/public expenditures on HIV and predictors
Fixed effects model Random effects model
(1) (2) (3) (4)
VARIABLES Ln(domestic public per capita) Ln(domestic public per capita) Ln(domestic public per capita) Ln(domestic public per capita)
Ln(Prevalence) 0.073 0.077 0.247* 0.252*
(.230) (.212) (.077) (.076)
Ln(GDP_cap) 1.201* 1.268* 1.090* 1.149*



















Constant −28.718 −10.30* −40.498 −10.061*
(47.722) (1.165) (38.911) (.817)
Best model1 FE FE RE RE
Overall R-squared 0.308 0.311 0.528 0.527
Observations 647 647 647 647
Number of countries 125 125 125 125
Robust standard errors in parentheses.
* p < 0.001.
1Indicated by the Hausman and Sargan-Hansen Tests.
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ments has been increasing and almost matched inter-
national aid over the past eleven years.
Discussion and conclusion
During the last decade, domestic resources have been in-
strumental in the efforts against HIV. Low- and middle-
income countries invested a total of US$ 43.5 billion
from domestic public sources in the last decade, reaching
US$ 6.6 billion in 2010, a three-fold increase in domestic
funding from the US$ 2.15 billion recorded in 2000. The
total amount from domestic sources and spent in the 125
countries analysed represents almost one half of thefunding available for HIV in these countries during the last
decade. In 2010 alone, low- and middle- income countries
(LMIC) contributed more than US $ 7.6 billion from pub-
lic (US$ 6.6 billion) and private sources (US$ 1.0 billion) to
their domestic HIV responses, while international funding
from bilateral and multilateral organizations and the phil-
anthropic sector contributed a total of US$ 7.5 billion for a
combined amount of US$ 15.1 billion in 2010 [6].
This analysis also found that GDP and HIV prevalence
are positively associated with the level of domestic
spending from public sources. A large body of evidence
shows a strong and positive correlation between national
income and national expenditures on health care and is
Figure 1 Domestic Public HIV Spending Globally and by Region (2000-2010).
Ávila et al. BMC Public Health 2013, 13:673 Page 5 of 8
http://www.biomedcentral.com/1471-2458/13/673a consistent finding of research [7,8]. Many argue that de-
veloping countries’ ability to take on a greater share of the
financial burden is critical to ensuring long-term sustain-
able financing and this may be possible with increased eco-
nomic growth.
In most countries the domestic HIV response is still
not commensurate with the magnitude of the epidemicTable 3 Domestic public spending per-capita in 2010
Co
Type of HIV epidemic Low-income (53) Lower-
GDP < US$ 935 GDP <
Generalized (39)** $0.81
Concentrated (47) $0.39
Low level (59) $0.05
Region
The Caribbean (12) $0.05
Eastern Europe and Central Asia (18) $0.28
Latin America (18) n/a
Middle East and North Africa (16) $0.05
Oceania(16) $0.28
Sub-Saharan Africa (43) $0.96
South and South-East Asia (20) $0.32
Western and Central Europe (14) n/a
ALL (145) $0.45
*Income level using the World Bank Atlas Method [13].
**Numbers in parenthesis are number of observations.[3]. Approaches that contribute to greater financial sus-
tainability of health programs have been extensively pub-
lished [9-12]. Governments in low-income countries
should mobilize domestic resources and analyse the con-
venience to implement innovative financing mechanisms
such as special levies on currency and financial transac-
tions, selling franchised products and services, mobileuntries income level *
middle-income (53) Upper-middle-income (39) ALL (145)













Figure 2 Relationship between GDP and per-capita Spending on AIDS in 2010.
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tobacco, alcohol and unhealthy food. Still, some low-
income countries cannot afford to fully support patients
on treatment from domestic resources alone and will need
external support.
There are several opportunities to increase public spend-
ing for the HIV response to reach the universal access tar-
gets for prevention, treatment and care. First, governments
can create fiscal space through fiscal instruments such as
external grants, domestic revenue mobilization, deficit fi-
nancing, reprioritization and raising efficiency of currentFigure 3 Percentage change in domestic public HIV expenditures durexpenditures. There may be substantial opportunity for
improving the efficiency of AIDS services, by providing
more services with existing resources. A recent study
evaluating efficiency of national HIV programs in 68 low-
and middle-income countries found only a moderate effi-
ciency of 49.8% in implementing AIDS programs [14].
Countries would also explore improving their capacity to
collect progressive and fair taxes from their citizens.
Middle-income countries, especially, have more room to
create a sustainable tax base. The World Bank estimates
that at least 30 per cent of GDP is needed to sustain aing 2005-2009 as compared to 2000-2004.
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below 20 percent of GDP [15].
Middle-income countries have the potential to in-
crease their domestic spending sustainably, especially
those less affected by the economic crisis, notably South
Africa [16]. A recently proposed HIV domestic priority
index shows a country’s ability to fund its own HIV re-
sponse [17]. Middle-income countries would seem to
have potential to increase their domestic spending sus-
tainably. China and India, two countries with increasing
epidemics, are spending at relatively low levels given
their disease burden and ability to pay. Therefore, they
could contribute more to the HIV response from do-
mestic resources. Even one of the weakest economies in
Africa, Zimbabwe, has shown unprecedented commit-
ment and has been able to augment the government
budgetary allocations to HIV programs by introducing
a monthly income tax from employee salaries [18].
This study describes public expenditures from an
international perspective and acknowledges that these
should provide information on beneficiary populations.
It has been shown that in spite of the fact that the HIV
epidemic in Latin America is driven by MSM and sex
workers, the majority of prevention spending is not
targeted at these groups [19]. At the country level,
benefit-incidence analyses (BIA) have the potential to
complement resource tracking activities by analyzing
who benefits from using health services. While trad-
itionally BIA has focused on pro-poor subsidies, the
same methodology can be used to assess how well
HIV programs are performing in terms of the distri-
bution of service benefits [20].
The economic outlook for low and middle income
countries is promising; even in Africa, GDP is expected
to grow by nearly 6 percent in 2013. This economic
growth is widespread across Africa and more than half
of all countries have improved governance with a major-
ity of countries improving in human development and a
growing middle class; these shifts suggest a dynamic
cycle of domestic growth [21-23].
Sustained increases in domestic funding for HIV were
observed in all regions during the last decade. Sub-
Saharan Africa has made a formidable effort character-
ized by higher domestic/public spending in spite of a
lower GDP per-capita and higher prevalence than any
other region. Despite huge income disparities, sub-
Saharan Africa and Latin America devoted significant
domestic resources to financing HIV-related activities,
the former under the pressure of high demand and a
high disease burden, the latter perhaps facilitated by
their developed health systems. Lower amounts were
spent in the Middle East, North Africa and Southeast
Asia relative to their populations, income level and
government revenue.Africa, in particular sub-Saharan Africa, is home to 80
percent of people living with HIV globally and one mil-
lion people living on less than a dollar a day. They spent
0.22 percent of their GDP, equivalent to US$ 2.5 billion or
US$ 3.45 per capita in 2010, the highest per capita spend-
ing amongst low- and middle-income countries. This re-
gion requires coordinated investments from international
donors as well as from national governments to curb the
continuous and chronic effects of the HIV epidemic.
The 2011 Political Declaration on HIV recognizes that
this worldwide commitment to the global HIV epidemic
has been unprecedented and represents the largest amount
dedicated to combating a single disease in history [24].
However, international assistance from bilateral organiza-
tions declined 10 percent between 2009 and 2010, following
years of steady increases in funding which increases the fi-
nancial burden on low- and middle-income countries in
the coming years [25]. Assistance by international organiza-
tions such as GF, UNITAID and PEPFAR have been critical,
accounting for most of the funding for HIV in many low
income and high burden countries and US$ 7.5 billion in
2010 alone. HIV directed foreign aid has significantly posi-
tive effects on a country’s treatment coverage rates [26]. In
fact, the expansion of access to HIV antiretroviral treatment
to 8 million people by the end of 2011 has resulted in the
reduction of HIV-related deaths by more than 20 per cent
in the past five years.
As in any study, there were several limitations. Domestic
spending is reported using government sources of informa-
tion, which in some countries lack comprehensive expend-
iture records and the accounting information systems do
not contain specific budgetary and expenditure lines related
to HIV. On balance, these data issues suggest that under-
estimation is more likely than overestimation and our
results represent lower bound estimates. Development part-
ners and governments are increasing efforts to strengthen
resource tracking over time. The estimation of missing data
points may be vulnerable to any unobserved effects that we
were not able to capture in the prediction model. In spite
of the relatively robust methodology and the use of panel
analysis based on a random effects model, there is always
the possibility of unobserved variables that were omitted
from the analysis. This analysis does not include out-of-
pocket expenditures; although out-of-pocket spending has
been found to vary from 23 to 68% of total health expendi-
tures, the proportion that households divert to the purchase
of condoms, HIV testing, clean syringes or other preventive
interventions is unknown [27].
Sustainable domestic investments are needed to achieve
a robust response to the HIV epidemic which will yield
long-term dividends. The high level of dependence on
international funding in low-income countries requires re-
thinking the global financial aid architecture to safeguard
the sustainability of HIV funding [28]. International donors
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finance influences domestic public finance and both do-
mestic and international sources should explore ways to
strategically increase their combined and complementary
investments. It is important to recognize that HIV is a
shared responsibility and ownership is instrumental. Coun-
tries should be able to access predictable and sustainable
HIV resources aligned with national development strat-
egies that maximize synergies and are implemented with
transparency and accountability [29].
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